KML001, a Telomere-Targeting Drug, Sensitizes Glioblastoma Cells to Temozolomide Chemotherapy and Radiotherapy through DNA Damage and Apoptosis

KML001, a Telomere-Targeting Drug, Sensitizes Glioblastoma Cells to Temozolomide Chemotherapy and Radiotherapy through DNA Damage and Apoptosis

Standard treatment for glioblastoma comprises surgical resection, chemotherapy with temozolomide, and radiotherapy. Nevertheless, majority of glioblastoma patients have recurrence from resistance to the cytotoxic conventional therapies. We examined combinational effects of KML001, an arsenic compoun...

Full description

Bibliographic Details
Main Authors: Woo, Seon Rang, Ham, Yunhee, Kang, Wonyoung, Yang, Heekyoung, Kim, Sujong, Jin, Juyoun, Joo, Kyeung Min, Nam, Do-Hyun
Format: Online
Language:English
Published: Hindawi Publishing Corporation 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176651/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176651/

Similar Items